Abstract: Disclosed are discreet functionally translocatable DNA segments, termed Sterol Regulatory Elements (SRE's), which are fused to heterologous structural genes to provide sterol regulatory capability to the thus formed hybrid gene. The hybrid genes respond to sterols by decreasing the production of messenger RNA. The SRE segments contain as their primary functional nucleotide sequence, a 16 bp sequence referred to as direct repeat 2, isolated from the 5' regions of the human LDL receptor gene. DNA segments which include this 16 nucleotide long sequence similarly confer sterol regulatory capability to previously known promoters such as the HSV TK promoter. Also disclosed are discreet sequences which confer positive transcription promotion to heterologous structural genes and promoters without conferring sterol responsivity. Methods are disclosed for employing these genetic control elements in a myriad of embodiments which provide for a fine-tune control of heterologous genes.
Type:
Grant
Filed:
June 1, 1990
Date of Patent:
June 1, 1993
Assignee:
Board of Regents, The University of Texas
Inventors:
Michael S. Brown, Joseph L. Goldstein, David W. Russell, Thomas C. Sudhof
Abstract: This invention is directed to genetically engineered proteins having human ChE activity, and more particularly, the activity of human AChE or human pseudo-ChE. The invention also provides for DNA sequences encoding such proteins, and more specifically DNA sequences comprising the entire coding region for encoding such complete proteins, and DNA expression vectors comprising such sequences. The invention also provides for DNA, which as been joined outside living cells, capable of infecting culturable cells, to be maintained therein and in progenies thereof which is adapted to encode such active proteins. The invention further provides culturable cells infected with recombinant DNA defined above, and to purified proteins having human ChE activity produced by such cells. There are further provided antibodies interacting with human AChE and pseudo-ChE and assays based on the use of such antibodies.
Abstract: A novel transposon useful for sequencing long DNAs is disclosed which comprises a partial sequence of transposon Tn5 with the oligonucleotide primers from phages SP6 and T7 inserted near the opposite ends, respectively, of said transposon Tn5.
Type:
Grant
Filed:
April 12, 1990
Date of Patent:
May 18, 1993
Assignee:
Washington University
Inventors:
Dilip K. Nag, Henry V. Huang, Douglas E. Berg
Abstract: The present invention provides a process for the cell fusion of strains of Phaffia rhodozyma thereby providing novel strains of Phaffia rhodozyma.
Abstract: The present invention relates to ars sequences which are efficacious in Yarrowia lipolytica, as well as to plasmids carrying these sequences.The strains of Y. lipolytica transformed with the said plasmids may be used in fermentation processes enabling proteins of industrial importance to be prepared.
Type:
Grant
Filed:
January 27, 1989
Date of Patent:
May 18, 1993
Assignee:
Institut National de la Recherche Agronomique (INRA)
Inventors:
Phillippe Fournier, Claude Gaillardin, Bernard Kudla, Henri Heslot
Abstract: The invention relates to novel DNA and amino sequences for a human MK protein. Also described are expression vectors and host cells useful in a method for production of the MK protein.
Abstract: N-substituted dialkanolamine may be converted to N-substituted-2-morpholone by the action of Gluconobacter oxydan ATCC #621 or Gluconobacter roseus IAM 1841.
Abstract: The nucleotide sequence of the genome for bovine diarrhea virus (BDV) is disclosed. The sequence permits design and construction of vaccines effective against BDV.
Type:
Grant
Filed:
July 6, 1990
Date of Patent:
April 27, 1993
Assignee:
Chiron Corporation
Inventors:
Andre Renard, Dino Dina, Joseph Martial
Abstract: A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.
Type:
Grant
Filed:
July 22, 1988
Date of Patent:
April 27, 1993
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Edward A. Berger, Bernard Moss, Thomas R. Fuerst, Ira Pastan, David Fitzgerald, Tamio Mizukami, Vijay K. Chaudhary
Abstract: Novel Bacillus thuringiensis genes encoding toxins which are active against lepidopteran insects have been cloned from novel lepidopteran-active B. thuringiensis microbes. The DNA encoding the B. thuringiensis toxins can be used to transform various prokaryotic and eukaryotic microbes to express the B. thuringiensis toxins. These recombinant microbes can be used to control lepidopteran insects in various environments.
Abstract: Viral protein T from Human Immunodeficiency Virus Type 1 (HIV-1) is disclosed. The protein has a molecular weight of approximately 17 kD and is produced by the vpt gene of HIV-1. This protein is antigenic. Vectors capable of expressing the vpt protein are also described.
Abstract: A transformation system is provided for C. tropicalis, comprising constructs and microorganisms, as well as methods for preparing constructs and microorganisms, and transforming microorganisms. Particularly, a yeast transformation system comprising auxotrophic hosts which are auxotrophic in either an amino acid, purine or pyrimidine pathways and employ DNA constructs comprising genes encoding biosynthetic enzymes which functionally complement the auxotrophies to prototrophies.
Type:
Grant
Filed:
July 27, 1989
Date of Patent:
April 20, 1993
Assignee:
Henkel Research Corporation
Inventors:
James M. Cregg, Martin A. Gleeson, Lisa Haas, Stephen Picataggio
Abstract: The present invention relates to a DNA segment encoding a recombinant HIV p24 protein or HIV p24-gp41 fusion protein and a recombinant DNA (rDNA) molecule capable of expressing either protein. Cells transformed with the rDNA, methods for producing the fusion protein and diagnostic methods and systems using the fusion protein are also described.
Type:
Grant
Filed:
April 26, 1989
Date of Patent:
April 20, 1993
Assignee:
Pharmacia Genetic Engineering, Inc.
Inventors:
Torsten B. Helting, Hakan Drevin, Michael F. Nunn
Abstract: What is described is a modified recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, having an internal core containing DNA from a non-pox source in a nonessential region of the poxvirus genome. The recombinant poxvirus is modified by disassociating the internal core from outer membranes of the poxvirus. The DNA codes for and expresses a gene product in a cell cultured in vitro and in a host in vivo without productive replication of the virus in the cell or in the host. What is also described is a vaccine containing the modified recombinant poxvirus for inducing an immunological response in a host inoculated with the vaccine.
Abstract: This invention relates to operator DNA specific for the repressor of .phi.105 and to the use thereof. The sequence of the operator DNA is 5'-GACGGAAATACAAG-3', 5', GTCGGAAATACAAT-3', 5'-GACGAAATTCAAG-3' or 5'-GTCGTGAATACCAT-3.
Abstract: This invention provides a plasmid identified as pHRTRX2 and deposited in E. coli HB101 under ATCC Accession No. 67828. The invention also provides for a polypeptide having HIV reverse transcriptase activity and for a method by which the polypeptide can be prepared which comprises growing a host cell comprising the plasmid pHRTRX2 under suitable conditions permitting production of the polypeptide and recovering the resulting polypeptide.
Type:
Grant
Filed:
December 28, 1988
Date of Patent:
April 13, 1993
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: Vectors are provided that are capable of expressing, in microbial transformants, a protein having the native amino acid sequence of a bioadhesive precursor protein of a marine animal selected from the group consisting of mussels, barnacles, and oysters. The bioadhesive precursor protein can be expressed in transformants, recovered and converted to a bioadhesive protein by hydroxylation.
Type:
Grant
Filed:
May 25, 1990
Date of Patent:
April 13, 1993
Assignee:
Enzon Labs Inc.
Inventors:
Kathy J. Maugh, David M. Anderson, Robert Strausberg, Susan L. Strausberg
Abstract: Vectors are provided that are capable of expressing, in microbial transformants, a protein having the native amino acid sequence of a bioadhesive precursor protein of a marine animal selected from the group consisting of mussels, barnacles, and oysters. The bioadhesive precursor protein can be expressed in transformants, recovered and converted to a bioadhesive protein by hydroxylation.
Type:
Grant
Filed:
August 16, 1991
Date of Patent:
April 13, 1993
Assignee:
Enzon Labs, Inc.
Inventors:
Kathy J. Maugh, David M. Anderson, Robert Strausberg, Susan L. Strausberg, Russ McCandliss, Tena Wei, David Filpula
Abstract: The invention is directed to a method of producing L-amino acids from .alpha.-ketocarboxylic acids by means of continuous fermentation with the aid of glutamate producing bacteria with biomass retention in which the cells are separated by microfiltration and/or centrifugal separators.
Type:
Grant
Filed:
May 1, 1987
Date of Patent:
April 6, 1993
Assignee:
Degussa AG
Inventors:
Christian Wandrey, Rolf Wichmann, Ulrich Groeger, Manfred Kircher, Wolfgang Leuchtenberger, Eberhard Breuker
Abstract: An rpoH gene that encodes a .sigma..sup.32 protein in which cysteine instead of arginine is at amino acid residue 268 was isolated from a mutant of Escherichia coli strain W3110. The rpoH gene has thymine instead of cytosine at the nucleotide position corresponding to 802 in the wild-type rpoH gene. Purified strains of E. coli W3110 and JM101 having a mutant rpoH gene in which thymine instead of cytosine is at the nucleotide position corresponding to 802 in a wild-type rpoH gene and a method for synthesis of proteins at enhanced levels are also disclosed. The method comprises introducing an expression vehicle into an E. coli strain containing the mutant rpoH gene of this invention.